Capsule Summary Slidesets

Share

Program Content

Activities

  • PARPi ± ICI in Recurrent EC
    Phase II Trial of Niraparib ± Dostarlimab in Patients With Recurrent Endometrial Carcinoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022
  • ASCENT Subgroups: SG vs CT
    ASCENT: Patient Subgroup Analyses of Sacituzumab Govitecan vs Single-Agent CT in Metastatic TNBC After ≥2 Prior CT Regimens
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2021

    Expires: June 07, 2022

  • GeparNUEVO Survival Results
    Phase II GeparNUEVO: Survival Outcomes With Durvalumab + Neoadjuvant CT vs Placebo + Neoadjuvant CT in Early TNBC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2021

    Expires: June 09, 2022

  • monarchE: Abema + ET post NAC
    monarchE: Subgroup Analysis of Abemaciclib + Adjuvant ET vs ET Alone in Patients With High-Risk HR+/HER2- Early Breast Cancer Who Received Prior Neoadjuvant Chemotherapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2021

    Expires: June 06, 2022

  • OTL38 + NIRF in OC
    Phase III Trial of Pafolacianine Sodium Injection (OTL38) for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2021

    Expires: June 08, 2022

  • TOTEM: Int vs Min FU for EC
    TOTEM: Intensive vs Minimalist Follow-up in Patients Treated for Endometrial Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2021

    Expires: June 09, 2022

  • Niraparib in <i>BRCA</i>m OC
    Niraparib in Patients with BRCA-Mutated Ovarian Cancer: Analysis of 3 Phase III Trials
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2021

    Expires: June 06, 2022

  • OlympiA
    Phase III OlympiA: Interim Analysis of Adjuvant Olaparib vs Placebo in BRCA-Mutated, HER2-Negative, High-Risk Early Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2021

    Expires: June 08, 2022

  • OUTBACK: CRT ± Adjuvant CT
    OUTBACK: Phase III Trial of CRT ± Adjuvant CT in Women With Locally Advanced Cervical Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022
  • MONALEESA-3 OS Update
    MONALEESA-3: Updated Overall Survival Analysis of Ribociclib + Fulvestrant vs Placebo + Fulvestrant in Postmenopausal Patients With HR+/HER2- Advanced Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2021

    Expires: June 10, 2022

  • EFFORT: Adavosertib ± Olaparib
    EFFORT: Phase II Study of the WEE1 Inhibitor Adavosertib ± Olaparib in PARPi-Resistant Ovarian Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme